Papillary thyroid cancers (PTC) are associated with a high prevalence of non-overlapping mutations of RET, TRK, RAS, and BRAF. As these signaling proteins form part of the classical MAPK pathway, this has been interpreted as evidence for a critical role of MAPK activation in initiation and maintenance of thyroid cancer. However thyroid cancers are also associated with mutations of genes encoding effectors signaling along the phosphatidylinositol 3-kinase (PI3K) pathway, yet whether constitutive activation of PI3K-AKT cooperates or not in certain thyroid tumors with MAPK to drive the tumorigenic process is unknown. RAS oncoproteins signal through both pathways, whereas oncogenic BRAF signals preferentially through MAPK, providing a useful paradigm in which to explore these interactions in mouse cancer models. The intensity of the oncogenic signal is an important variable, and we intend to look at these interactions through genetic manipulations that approximate pathophysiological conditions. For this we have generated mice with a conditionally gene-targeted activating mutation of H-ras, and obtained an analogous model for B-raf. 1) We will explore whether these oncoproteins initiate cell transformation through induction of a DNA damage response, followed by senescence. 2) We will expand on our observation that a thyroid-specific knock-in of H-ras markedly increases mutation frequency in mice, by using mouse reporter strains to test for different mutation types. 3) We will then examine whether H-ras or B-raf activation cooperate with loss of the tumor suppressor Pten to promote thyroid tumorigenesis in different genetic backgrounds, and explore the mechanisms involved. 4) Finally, we will test the hypothesis that genetic determinants of MAPK and PI3K activation in a large panel of suitably genotyped human thyroid cancer cell lines predicts responsiveness to pathway inhibitors. Public Health Relevance Statement: In this proposal, we intend to use mouse models to reconstruct the very first stages of thyroid cancer development. The very first genetic changes that get the tumor started are particularly important, because cancers remain dependent on their abnormal activity even though they continue to accumulate damage of other genes over time. This will help us decide what key genetic abnormalities to focus on as we develop specific treatments for patients with the most advanced forms of the disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072597-16
Application #
8197888
Study Section
Integrative and Clinical Endocrinology and Reproduction Study Section (ICER)
Program Officer
Yassin, Rihab R,
Project Start
1996-12-21
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2013-12-31
Support Year
16
Fiscal Year
2012
Total Cost
$450,546
Indirect Cost
$209,612
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Malaguarnera, Roberta; Chen, Kuen-Yuan; Kim, Tae-Yong et al. (2014) Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab 99:E1976-87
Sabra, M M; Dominguez, J M; Grewal, R K et al. (2013) Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 98:E829-36
Landa, Inigo; Ganly, Ian; Chan, Timothy A et al. (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-6
Ryder, Mabel; Gild, Matti; Hohl, Tobias M et al. (2013) Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One 8:e54302
Montero-Conde, Cristina; Ruiz-Llorente, Sergio; Dominguez, Jose M et al. (2013) Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3:520-33
Ricarte-Filho, Julio C; Matsuse, Michiko; Lau, Christopher et al. (2012) Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. Int J Cancer 130:2215-7; author reply 2217-8
Madsen, Lars Wichmann; Knauf, Jeffrey A; Gotfredsen, Carsten et al. (2012) GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153:1538-47
Knauf, J A; Sartor, M A; Medvedovic, M et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFýý signaling. Oncogene 30:3153-62
Chakravarty, Debyani; Santos, Elmer; Ryder, Mabel et al. (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700-11
Franco, Aime T; Malaguarnera, Roberta; Refetoff, Samuel et al. (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 108:1615-20

Showing the most recent 10 out of 40 publications